Inhalerx Ltd (irx) Logo

Inhalerx Ltd (IRX)

___:___ · Healthcare
Take a deeper look into...
EVE Investments Ltd (EVE) Logo

EVE Investments Ltd

EVE:ASX · Consumer Defensive

EVE harvest create innovative products to improve the well-being of consumers globally while being committed to high quality and sustainable.

IRX Chart


IRX's Principal Activity is the developing and commercializing medical diagnostic and monitoring technology and digitally enabled drug delivery systems.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) +46.65%


Market Capitalisation
ASX Rank 1,817 of 2,316
Sector Rank 170 of 198

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies CTE / AJJ / AGN
EPS -$0.008
DPS $0.00
NTA per share $0.02

Broker Consensus

IRX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

InhaleRx Limited (IRX, formerly Lifespot Health Ltd ) focus on medical inhalation devices for the delivery of prescribed medicines.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Melbourne VIC 3000
Registry Computershare
Auditor HLB Mann Judd
Date Listed 11 Jan 2017

Upcoming Calendar (Forecasted)

Date Event
25/02/2022 Report (Prelim)
30/03/2022 Report (Annual)
31/08/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Sean Williams Non-Executive Chairman,Non-Executive Director Jul 2021 Director Bio icon

Mr Sean Williams

Non-Executive Chairman,Non-Executive Director

Mr Williams is an experienced senior executive who has had a career across the supply chain, health, pharmaceutical and investment management sectors. Most recently Sean was CEO of an agricultural investment company. The earlier parts of Sean's career were spent in senior operational and finance roles with multi-national and listed local companies, having initially commenced his career with KPMG. He spent a number of years as General Manager Finance and General Manager - Hospital Pharmacy & Dental Distribution Services for Symbion Pharmacy Services. He has also worked in private equity and with private equity investments, including 5 years as CFO of Silk Logistics Group, and has focused on entrepreneurial ventures, including as a business owner, founder and CEO of businesses featuring management buy-outs, business mergers and start-ups.

Dr Andrew Saich Non-Executive Director Jul 2021 Director Bio icon

Dr Andrew Saich

Non-Executive Director

Dr Saich has worked in both large and small pharmaceutical companies. He has been involved in pharmaceutical Industry for over 20 years and has gained experience of international management, medicines commercialization and pharmaceutical R&D. Andrew is currently Chief Medical Officer of Return Health, a US based biotech company developing novel psychedelic treatments for patients with dementia and a co-founder of Diligenc. Capital, a cannabinoid prescription medicines investment group and Diligenc. Pathways, a consultancy comprising senior cannabinoid specialists from the ex-GW Pharmaceuticals team. In previous roles, Andrew was the European Medical Director responsible for establishing the Intercept Pharmaceuticals international medical and commercial organization as the company expanded from its New York corporate headquarters into thirteen countries across Europe. In 2016 Andrew created and led the GW Pharmaceuticals International Medical organization in preparation for the launch of Epidyolex (cannabidiol) for the treatment of rare and debilitating drug-resistant epilepsies. GW Pharmaceuticals (recently acquired by Jazz Pharmaceuticals) was the world leader in the development of cannabinoid medicines and Andrew was a senior member of the international management team, the strategic launch team, the Clinical Development Committee and the Corporate Drug Safety team. Andrew networks with politicians, governmental organizations and pharmaceutical regulators during his time at GW and lead both the global investigator initiated studies program and the global compassionate use program. Post GW Pharmaceuticals Andrew became Chief Medical Officer of Senzer Pharmaceuticals with responsibility for a clinical development program utilizing inhaled cannabinoids.

Mr Darryl Davies Non-Executive Director Jul 2021 Director Bio icon

Mr Darryl Davies

Non-Executive Director

Mr Davies has over 15 years' experience in Psychology, Healthcare and Harm Minimisation. He joined Addaction, the substance misuse NGO in the UK that works to transform the lives of people affected by drug and alcohol problems. Darryl developed his experience of harm minimization in Thailand where he worked at several detoxification centers supporting patients from around the world via a combination of Western and Eastern practices. Since migrating to Australia in 2011, Darryl has worked in several for-purpose, NGO roles including Compliance, Business Development, Corporate Relationships, and Educational Social Enterprise. Transitioning into new challenges, Darryl started working with a wellness device start-up in 2016, before becoming something of a medicinal cannabis industry early adopter. Recognizing that changing perceptions was paramount to industry development; Darryl lent on his experience and coordinated a range of targeted cannabis educational events nationally. Darryl has designed and facilitated such events for the State Government and has led doctor education initiatives in regional areas. He is also recognized for his work as a Director with Israeli Company, Cann10 having delivered Australia's first university-based Cannabis Leadership Program. In early 2018, Darryl Co-founded private Medicinal Cannabis Service Provider, Cannvalate Pty Ltd. He has managed the company's award-winning patient access and distribution programs as well as developing the CRO, Medicinal Cannabis Research Collaboration (MCRC). His role of Chief Operating Officer has enabled him to develop a sound understanding of the challenges of scaling effective departments to solve problems in the Australian Medicinal Cannabis landscape. Darryl has global industry connections and is nominated the Australian Director of Canadian manufacturing leader, The Valens Company (VLNCF) whereby he advises on their Australian market entry strategy and he also sits on the Board of Directors for New Zealand cultivation company, Greenfern Industries Limited.

Ms Elizabeth Spooner Joint Company Secretary Jul 2021
Ms Nova Taylor Joint Company Secretary Jan 2021
Mr Matthew Golden Chief Executive Officer Oct 2020

Director Transactions

IRX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
11/10/21 Darryl Davies Buy +305,248 $0.105 $32,051 On-market trade
24/08/21 Darryl Davies Buy +1,025,000 $0.097 $99,927 On-market trade
05/01/21 Rodney Hannington Issued 55,000 $0.07 $3,850 Rights issue

Director Interests

The current holdings of IRX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Darryl Davies 11/10/2021 N/A 33,524,924 N/A N/A
Sean Williams 26/07/2021 0 N/A N/A N/A
Andrew Saich 20/07/2021 0 N/A N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Mar 3, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Cannvalate Pty Ltd 30,211,050 17.93%
M I D Wealth Pty Ltd 16,375,000 9.72%
ELA Capital Inc 11,329,573 6.73%
Pyxis Holdings Pty Ltd (The Mapletree A/C) 10,512,500 6.24%
10 Bolivianos Pty Ltd 10,357,755 6.15%
J P Morgan Nominees Australia Pty Limited 6,574,417 3.90%
Orca Capital Gmbh 6,250,000 3.71%
BNP Paribas Noms Pty Ltd (Drp) 4,472,846 2.66%
Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 3,920,394 2.33%
Ancan Investments Pty Ltd (A & A Cannavo Share A/C) 3,687,500 2.19%
Bliss On Banksia Hairdressing Pty Ltd (The Stefanest Egg Sfund A/C) 2,662,118 1.58%
Mr Niv Dagan 2,342,012 1.39%
HSBC Custody Nominees (Australia) Limited 2,203,190 1.31%
Dr David James Walland 2,122,137 1.26%
Mr Piper Belesprit Madison 2,000,038 1.19%
J & W Crock Super Pty Ltd (J & W Crock Super Fund A/C) 1,526,542 0.91%
Mr Peter Steinmetz 1,500,000 0.89%
Nevertity Holdings Pty Ltd (J Isac Family A/C) 1,387,476 0.82%
Mr Shawn Yapp 1,350,000 0.80%
Sacco Developments Australia Pty Limited (The Sacco Family A/C) 1,150,000 0.68%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 23 119 157 297 120 716

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
M I D Wealth Pty Ltd 03/03/2021 13,100,000 7.78
Ela Capital Inc 03/03/2021 14,515,743 8.62
Pyxis Holdings Pty Ltd 03/03/2021 8,909,441 5.29
Cannvalate Pty Ltd 11/10/2021 33,524,924 19.90
Niv Dagan 18/08/2021 14,901,280 8.85

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
11-10-21 Cannvalate Pty Ltd 3,335,302 19.21 19.90
18-08-21 Niv Dagan 5,283,082 7.14 8.85
19-01-21 Ela Capital Inc 14,515,743 -- 8.60
05-01-21 Cannvalate Pty Ltd 6,077,525 17.89 19.21
13-11-20 M I D Wealth Pty Ltd 13,100,000 -- 9.72
13-11-20 Pyxis Holdings Pty Ltd 309,426 7.32 6.61
12-11-20 Niv Dagan 1,351,608 9.43 7.14
06-11-20 Cannvalate Pty Ltd 112,097 19.72 17.89

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
IRX Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.